Novelion Therapeutics Inc (NVLNF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2017 | 09-2017 | 06-2017 | 03-2017 | 12-2016 | |
| Sales | 38,908 | 28,669 | 40,877 | 29,984 | 0 |
| Cost of Goods | 16,993 | 29,505 | 14,277 | 16,445 | N/A |
| Gross Profit | 21,915 | -836 | 26,600 | 13,539 | N/A |
| Operating Expenses | 36,872 | 39,068 | 38,649 | 35,647 | 27,934 |
| Operating Income | -13,964 | -39,399 | -11,772 | -21,663 | -14,360 |
| Interest Expense | 10,315 | 9,897 | 9,613 | 9,212 | 3,199 |
| Other Income | -468 | 49 | 75 | 52 | -1,792 |
| Pre-tax Income | -24,747 | -49,247 | -21,310 | -30,823 | -19,351 |
| Income Tax | -179 | 497 | 126 | 139 | 569 |
| Net Income Continuous | -24,568 | -49,744 | -21,436 | -30,962 | -19,920 |
| Net Income | $-24,568 | $-49,744 | $-21,436 | $-30,962 | $-19,920 |
| EPS Basic Total Ops | -1.32 | -2.67 | -1.15 | -1.67 | -1.58 |
| EPS Basic Continuous Ops | -1.32 | -2.67 | -1.15 | -1.67 | -1.57 |
| EPS Diluted Total Ops | -1.32 | -2.67 | -1.15 | -1.67 | -1.58 |
| EPS Diluted Continuous Ops | -1.32 | -2.67 | -1.15 | -1.67 | -1.57 |
| EBITDA(a) | $-7,092 | $-32,647 | $-5,015 | $-14,942 | $-25,621 |